𝔖 Bobbio Scriptorium
✦   LIBER   ✦

New antiangiogenic agents for renal cell carcinoma: Interferon alfa and thalidomide

✍ Scribed by Ronald M. Bukowski


Book ID
107546275
Publisher
Current Science Inc.
Year
2004
Tongue
English
Weight
92 KB
Volume
6
Category
Article
ISSN
1523-3790

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Pilot trial of bone-targeted therapy wit
✍ Nizar Tannir; Eric Jonasch; Lance C. Pagliaro; Paul Mathew; Arlene Siefker-Radtk πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 482 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The purpose of the study was to evaluate the efficacy and safety of a bone‐targeted regimen consisting of zoledronate, thalidomide, and interferon‐γ in patients with renal cell carcinoma and bone metastases. ## METHODS. Eligible patients had radiographic evidence of bo

Pulmonary Sarcoidosis Following Interfer
✍ Ehtesham A. Abdi; Gia-Khanh Nguyen; Roberta N. Ludwig; William J. Dickout πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 663 KB

A 57-year-old woman developed pulmonary sarcoidosis during therapy with interferon /3 for advanced renal cell carcinoma metastatic to mediastinal lymph nodes. The possible role of interferon /3 in the pathogenesis of sarcoidosis in this patient is discussed.

Further experience with recombinant inte
✍ S. D. FossΓ₯; S. T. De Garis πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 French βš– 404 KB

Thirty-three patients with measurable metastatic renal cell carcinoma were entered into 2 consecutive phase II protocols using interferon alfa-2a. In protocol I, 20 patients were treated with interferon alfa-2a at a dose of 36 x I06 IU i.m. t.i.w. Vinblastine was also given t o 18 of these patients